The 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene fluorescent dyes (BODIPYs) were first synthesized almost 50 years ago; however, the exploration of their technological application has only begun in the last 20 years. These dyes possess interesting photophysical properties, increasing interest in their application as fluorescent markers and/or dyes. Herein, we report the synthesis of tetramethyl BODIPY and four meso-substituted dyes (2-thienyl, 4-pyridinyl, 4-fluorophenyl and 4-nitrophenyl derivatives). Their photophysical characterization (absorption spectra, emission spectra, fluorescence quantum yields and time-resolved fluorescence) and solvatochromic behavior were studied. Absorption and emission were barely affected by substituents, with a slightly higher stokes shift observed in the substituted dyes. Substitutions could be associated with a shorter fluorescence lifetime and lower quantum yields. Good correlations were observed between the Catalán solvent descriptors and the photophysical parameters. Also, better correlation was observed between the solvent polarizability descriptor (SP) and photophysical parameters. Overall, only slight solvatochromism was observed. The 4-pyridinyl derivative was the subject of a relatively significant solvatochromism regarding the wavelengths of the emission spectra, with the observation of a bathochromically shifted emission in methanol. The fluorescence quantum yield of the 4-nitrophenyl substituted BODIPY was approximately 30 times higher in hexane, which may be of interest for practical applications.

It is known that aziridines and nitrogen mustards exert their biological activities, especially in chemotherapy, via DNA alkylation. The studied scaffold, 2-phenyl-1-aziridine, provides a distinct conformation compared to commonly used aziridines, and therefore, leads to a change in high-strained ring reactivity towards biological nucleophiles, such as DNA. The above series of compounds was tested in three breast cell lines: MCF-10, a healthy cell; MCF-7, a hormone responsive cancer cell; and MDA-MB-231, a triple negative breast cancer cell. Both aziridines and their precursors, β-amino alcohols, showed activity towards these cells, and some of the compounds showed higher selectivity index than cisplatin, the drug used as control. When the type of cell death was investigated, the synthesized compounds demonstrated higher apoptosis and lower necrosis rates than cisplatin, and when the mechanism of action was studied, the compounds were shown to interact with DNA via its minor groove instead of alkylation or intercalation.

We review progress in the application of fragment-based drug discovery (FBDD) to epigenetic drug discovery (EPIDD) targeted at epigenetic writer and eraser enzymes as well as reader domains over the last 15 years. The greatest successes to date are in prospecting for bromodomain binding ligands. From a diverse array of fragment hits, multiple potent and selective compounds ensued, including the oncology clinical candidates mivebresib, ABBV-744, pelabresib, and PLX51107.

No abstract